Another one of the more common high blood pressure medicines are ones known as beta-blockers. Some of the most common brands include:
Levatal
Visken
Cartrol
Inderal
Sectral
Corgard
Blocadren
Coreg
Kerlone
There are numerous benefits with beta-blockers in treating high blood pressure symptoms. Among them are:
-The ability to slow down specific metabolic processes. …
Flamel Technologies (Nasdaq:FLML) today announced its financial
results for the second quarter of 2008 as well as the signing of two
further Medusa contracts with two current partners. Flamel currently
is working on Medusa projects with four of the top-ten and six of the
top-twenty pharmaceutical companies in the world.
Flamel reported total revenues of $9.2 million, compared to $7.4
million in the second quarter of 2007. P…
To: NATIONAL EDITORS
Contact: Jennifer Page of the Pharmaceutical Research and
Manufacturers of America, 1-202-835-3460
Honors Coreg Researchers at Capitol Hill Press Conference
WASHINGTON, Feb. 7 /PRNewswire-USNewswire/ — Pharmaceutica…
Q: I thoroughly enjoy your discussions on heart topics, and wondered if you could address one of sudden interest to me. It concerns ejection fraction. Echocardiograms indicate that mine has dropped from approximately 43 percent to an alarming 34 pe…
Dec. 6, 2001 — Heart failure is a major health concern in the U.S. Nearly 5 million people are living with this problem, and a half million are diagnosed every year. The most common cause is blockage of arteries in the heart, leading to damaged heart muscle and a weak pump. Other causes include heart infections — called endocarditis — and high blood pressure.
With all the development in heart …
GlaxoSmithKline P.L.C. said yesterday that it would buy a New Jersey firm with the U.S. rights to the triglyceride-fighter Lovaza for $1.65 billion in cash. Reliant Pharmaceuticals Inc., of Liberty Corner, has four artery- or heart-related medications on the market, including fast-growing Lova…
LYON, France — Flamel Technologies (Nasdaq: FLML) is pleased that GlaxoSmithKline yesterday announced the U.S. nationwide availability of COREG CR[TM] (carvedilol phosphate) extended release tablets for use in treating three cardiovascular conditions:
* High blood pressure, also known as hypertension;
…
PHILADELPHIA — GlaxoSmithKline PLC (GSK) has launched once-daily Coreg CR as a treatment for three cardiovascular conditions. Previously the pill had to be taken twice a day.
The Food and Drug Administration approved the extended-release beta-blocker to treat high blood pressure, heart attacks that reduce the ability of the heart to pump blood, and mild-to-severe heart failure.
The compa…
